Diogo Martins Branco

📢#CancerTherapy claiming #TumourAgnostic potential❓ ✔ ORR≥20% in 2/3 of tumour types investigated (≥4) with ≥5 evaluable patients per tumour type 🔓@myESMO Tumour-Agnostic Classifier & Screener (ETAC-S) @Annals_Oncology @BenWestphalen @VivekSubbiah @GPentheroudakis et al

Molecular and clinical analyses of gene fusions identify therapeutic targets in paired primary and metastatic breast cancer from the AURORA program (BIG 14-01) aacrjournals.org/clincancerres/… This study uses AURORA multi-omics 🧬data to characterize gene fusions in metastatic #BreastCancer and their clinical relevance. Analysis of RNA sequencing from primary and metastatic tumors revealed a higher gene fusion burden in metastases, with acquired fusions linked to genomic instability and subtype-specific copy-number gains, particularly involving genes within the same topologically associating domain. These fusions were associated with poorer prognosis in ER-positive/HER2-negative tumors, with ESR1 fusions marking especially aggressive disease, highlighting gene fusions as potential drivers of progression and therapeutic targets. Chiara Biagioni @Fimereli_Danai @AlexIrrthum @AngelZotano @Carmela_surgery @DMBranco @ElisaAgostinett @ZoppoliGabriele @AnaVivancosVHIO @MOliveira_MD @curijoey @c_sotiriou @aftimosp Matteo Benelli @UNI_FIRENZE

👏 #MatteoBenelli #ChiaraBiagoni 🙏 @AngelZotano @Carmela_surgery @DMBranco @ElisaAgostinett @ZoppoliGabriele @AnaVivancosVHIO @MOliveira_MD @c_sotiriou @curijoey

📢 Applications open for the #MCCRworkshop! A week-long workshop to master #ClinicalTrialDesign & learn from global experts. 🔗 Apply now: ow.ly/YGax50XHtfu 📅 13–18 June 2026 ✅ Apply by 30 January #ClinicalTrial #ClinicalResearch

New Living Guideline on Early & Locally Advanced #NSCLC! This dynamic resource integrates all recommendations and algorithms from the recently updated #ClinicalPracticeGuideline, supporting clinicians in evidence-based decision-making for optimal patient care. 🔗 ow.ly/sXaz50XA69A

👉 Join the upcoming #ESMOGuidelines Webinar to explore #realworldcases, expert insights & the latest treatment strategies in #lymphoma 🔗 Free with your ESMO account: ow.ly/Q38B50XuGcP

📣 Registration is open for the ESMO Sarcoma and Rare Cancers Congress 2026! Join us 12–14 March in Lugano. ⏰ Early rates end 14 Jan 2026 23:59 CET – secure your seat now! #ESMORareCancers26 #esmomeetings 🔗 ow.ly/g8qv50XocO5

🆕new article in press: ESMO Basic Requirements for AI-based Biomarkers In Oncology (EBAI). @jnkath @mihaela_aldea @BenWestphalen. Read it here: annalsofoncology.org/article/S0923-… 📷

Still buzzing from #ESMO25 💥 Inspiring science and conversations — a privilege to connect with the @myESMO Precision Oncology Task Force 🧬 Grateful to be part of the mission to bring precision oncology to every patient!Energised for what’s next 🔬💫 @VivekSubbiah @BenWestphalen

Proud to be part of this evolutionary moment of @myESMO, turning evidence into action at point of care, under the visionary leadership of our Board (@FAndreMD, @curijoey, @AndresC27622123, @E_de_Azambuja, @Prof_Nadia_H, @jeanyvesblay) and inspiring mentorship of @GPentheroudakis

#ESMO25 it's a wrap 🎬 Special edition marking 50y of @myESMO 📍 10y of ESMO membership 👨🏻‍🎓 4 of MedOnc training&education 👨🏻‍⚕️ 6 of Board&ESMO Certification 🏥 5 of clinical cancer care 🇵🇹 📊 3 of clinical cancer research 🇧🇪 🌐 2 of ESMO Sci&Med Division 🇨🇭 #myESMOStory 🧵

🆕article in press: ESMO-ESTRO consensus statements on the safety of combining radiotherapy with immune checkpoint inhibitors, VEGF(R) inhibitors, or multitargeted tyrosine kinase inhibitors @myESMO @ESTRO_RT doi.org/10.1016/j.anno…

📣 #ESMOImmuno25: Final call! Only 24 hours left to submit your studies. Don’t miss your chance to connect with leading researchers, share your discoveries and contribute to shaping the future of cancer care. ⏰ Deadline 30 September 🔗 ow.ly/Tl4z50X2GRs

#ESMOAmbassadors #bcsm Both DB-11 (neoadj T-DXd) and DB-05 (residual disease T-DXd) will be presented back-to-back at #ESMO25, Saturday October 18th 4:30pm in the presidential #1 session . This is the presidential session for #bcsm folks to attend! Put it on your 📅!

🤖 #ESMOAI25: Your not to miss sessions! Multimodal AI for clinical decision support, featuring discussions about assistants for molecular tumour boards, multimodal integration and more! Register by 22 October and benefit from advantageous fees #HealthAI 🔗 ow.ly/fIKJ50WR8rn

📣 Abstract submission is OPEN! Join us at the ESMO Sarcoma and Rare Cancers Congress 2026 in Lugano, 12–14 March. ⏰ Abstract submission ddl: 9 December, 21:00 CET. 👉 Don’t miss your chance to present at this global oncology forum! #ESMORareCancers26 🔗 ow.ly/VXqA50WVzYH

Abstract submission to ESMO Breast 2026 is now open (deadline: 1/27/26, LBA deadline: 3/31/26) esmo.org/meeting-calend…

📣 Updated ESMO #ClinicalPracticeGuideline recommendations in #MetastaticBreastCancer: focusing on #PrecisionOncology and a #PatientCentricCare, this commentary highlights key updates of the ESMO Living Guideline algorithms, focusing on HR+/HER2- disease. #ESMOGuidelines #TargetedTherapy #HRpositive #HER2negative #CancerBiomarkers 🔗 ow.ly/nFCu50WEpqk

📣 ESMO Living Guidelines on Metastatic Colorectal Cancer v1.3: Updated recommendations and algorithms for the treatment of patient with BRAF-mut. 🔗 ow.ly/Vvst50WpHFh #ESMOGuidelines @ChiaraCrem1 @erikamartin3lli @AndresC27622123

📣 #ESMO25: Be where the latest breakthroughs are being shared—in real time, with real impact. Last chance to register at the most advantageous fees! ⏰ Deadline: 16 July 2025 🔗 ow.ly/5PAL50WfVKu

🤖 #ESMOAI25: Help us advance cancer care through technology 🚨 Your insights will help drive the evolution of AI and digital solutions in oncology. ⏰ Submit your research by 2 September 2025. #HealthAI 🔗 ow.ly/pjIQ50Wia3a